SCHEMBL24258083

SCHEMBL24258083

CC(=O)Nc1cc(Cc2nc(-c3ccc(=O)[nH]c3)no2)ccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC1 P07992 1/20 0.43
ERCC4 Q92889 1/20 0.43
KMT2A Q03164 4/20 0.40
TSHR P16473 3/20 0.40
MAPK1 P28482 3/20 0.40
MEN1 O00255 3/20 0.40
LMNA P02545 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
MAPT P10636 5/20 0.39
ALDH1A1 P00352 4/20 0.39
HSD17B10 Q99714 1/20 0.39
THRB P10828 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
ALOX15 P16050 1/20 0.39
RAB9A P51151 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
HPGD P15428 1/20 0.37
PKM P14618 1/20 0.37
TP53 P04637 1/20 0.37
ROCK2 O75116 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24258053 0.83 ERCC1 (0.49) ERCC1ERCC4KMT2ATSHRMAPK1
SCHEMBL24258072 0.78 MAPK1 (0.58) ERCC1ERCC4KMT2ATSHRMAPK1
SCHEMBL26004727 0.77 MAPT (0.47) ERCC1ERCC4KMT2ATSHRMAPK1
SCHEMBL26004940 0.77 ALDH1A1 (0.39) ERCC1ERCC4KMT2ATSHRMAPK1
SCHEMBL24258021 0.76 ERCC1 (0.48) ERCC1ERCC4KMT2ATSHRMAPK1
SCHEMBL24258048 0.76 TDP1 (0.57) KMT2ATSHRMAPK1MEN1LMNA
SCHEMBL24258039 0.75 ERCC1 (0.45) ERCC1ERCC4KMT2ATSHRMAPK1
SCHEMBL26006746 0.74 ERCC1 (0.39) ERCC1ERCC4KMT2ATSHRMAPK1
SCHEMBL24258084 0.73 S1PR1 (0.58) KMT2ATSHRMAPK1MEN1L3MBTL1
SCHEMBL24258023 0.72 S1PR1 (0.43) ERCC1ERCC4KMT2ATSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
WO-2022035805-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP1, USP18 ERCC1 2832/4885ERCC4 1843/4885KMT2A 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.